Microglial KCa3.1 channels as a potential therapeutic target for Alzheimer's disease

International Journal of Alzheimer's Disease

Volumn , Issue , 2012, Pages

  Maezawa, Izumi ^a,b   Jenkins, David Paul ^a   Jin, Benjamin E ^a   Wulff, Heike ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [(2 CHLOROPHENYL)DIPHENYLMETHYL] 1H PYRAZOLE; CLOTRIMAZOLE; CYCLOHEXADIENE LACTONE; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KCA3.1; SENICAPOC; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; CEREBROVASCULAR ACCIDENT; HUMAN; INHIBITION KINETICS; MICROGLIA; MILD COGNITIVE IMPAIRMENT; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW; SICKLE CELL ANEMIA; TRAUMATIC BRAIN INJURY;

EID: 84862277780     PISSN: None     EISSN: 20900252     Source Type: Journal    
DOI: 10.1155/2012/868972     Document Type: Review

References (63)

1. Shineman D. W., Basi G. S., Bizon J. L., Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies Alzheimer's Research Therapy 2011 3 5, article 28
2. Golde T. E., Schneider L. S., Koo E. H., Anti-A therapeutics in alzheimer's disease: the need for a paradigm shift Neuron 2011 69 2 203 213
3. Reitz C., Brayne C., Mayeux R., Epidemiology of Alzheimer disease Nature Reviews Neurology 2011 7 3 137 152
4. Mondragn-Rodrguez S., Basurto-Islas G., Lee H. G., Perry G., Zhu X., Castellani R. J., Smith M. A., Causes versus effects: the increasing complexities of Alzheimer's disease pathogenesis Expert Review of Neurotherapeutics 2010 10 5 683 691
5. Jellinger K. A., Neuropathological aspects of Alzheimer disease, Parkinson disease and frontotemporal dementia Neurodegenerative Diseases 2008 5 3-4 118 121 (Pubitemid 351347827)
6. Chui H. C., Zheng L., Reed B. R., Vinters H. V., Mack W. J., Vascular risk factors and Alzheimer's disease: are these risk factors for plaques and tangles or for concomitant vascular pathology that increases the likelihood of dementia? An evidence-based review Alzheimer's Research Therapy 2012 3 6, article 36
7. Schneider J. A., Arvanitakis Z., Bang W., Bennett D. A., Mixed brain pathologies account for most dementia cases in community-dwelling older persons Neurology 2007 69 24 2197 2204 (Pubitemid 350294674)
8. Querfurth H. W., LaFerla F. M., Alzheimer's disease The New England Journal of Medicine 2010 362 4 329 344
9. Chen Q., Prior M., Dargusch R., Roberts A., Riek R., Eichmann C., Chiruta C., Akaishi T., Abe K., Maher P., Schubert D., A novel neurotrophic drug for cognitive enhancement and Alzheimer's disease PLoS ONE 2011 6, article e27865
10. Hardy J., Selkoe D. J., The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics Science 2002 297 5580 353 356 (Pubitemid 34790756)
11. Demuro A., Mina E., Kayed R., Milton S. C., Parker I., Glabe C. G., Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers The Journal of Biological Chemistry 2005 280 17 17294 17300 (Pubitemid 41389198)
12. Demuro A., Smith M., Parker I., Single-channel Ca 2+ imaging implicates A 142 amyloid pores in Alzheimers disease pathology Journal of Cell Biology 2011 195 515 524
13. Mauler F., Hinz V., Horvth E., Schuhmacher J., Hofmann H. A., Wirtz S., Hahn M. G., Urbahns K., Selective intermediate-/small-conductance calcium-activated potassium channel (KCNN4) blockers are potent and effective therapeutics in experimental brain oedema and traumatic brain injury caused by acute subdural haematoma European Journal of Neuroscience 2004 20 7 1761 1768 (Pubitemid 39471569)
14. McGeer E. G., McGeer P. L., Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy Journal of Alzheimer's Disease 2010 19 1 355 361
15. Meda L., Cassatella M. A., Szendrei G. I., Otvos L., Baron P., Villalba M., Ferrari D., Rossi F., Activation of microglial cells by -amyloid protein and interferon- Nature 1995 374 6523 647 650
16. Jimenez S., Baglietto-Vargas D., Caballero C., Moreno-Gonzalez I., Torres M., Sanchez-Varo R., Ruano D., Vizuete M., Gutierrez A., Vitorica J., Inflammatory response in the hippocampus of PS1M146L/APP 751SL mouse model of Alzheimer's disease: age-dependent switch in the microglial phenotype from alternative to classic Journal of Neuroscience 2008 28 45 11650 11661
17. Maezawa I., Zimin P. I., Wulff H., Jin L. W., Amyloid- protein oligomer at low nanomolar concentrations activates microglia and induces microglial neurotoxicity The Journal of Biological Chemistry 2011 286 5 3693 3706
18. Rogers J., The inflammatory response in Alzheimer's disease Journal of Periodontology 2008 79 8 1535 1543
19. Okello A., Edison P., Archer H. A., Turkheimer F. E., Kennedy J., Bullock R., Walker Z., Kennedy A., Fox N., Rossor M., Brooks D. J., Microglial activation and amyloid deposition in mild cognitive impairment: a PET study Neurology 2009 72 1 56 62
20. Sastre M., Richardson J. C., Gentleman S. M., Brooks D. J., Inflammatory risk factors and pathologies associated with Alzheimer's disease Current Alzheimer Research 2011 8 2 132 141
21. El Khoury J., Luster A. D., Mechanisms of microglia accumulation in Alzheimer's disease: therapeutic implications Trends in Pharmacological Sciences 2008 29 12 626 632
22. Cameron B., Landreth G. E., Inflammation, microglia, and alzheimer's disease Neurobiology of Disease 2010 37 3 503 509
23. Hickman S. E., Allison E. K., El Khoury J., Microglial dysfunction and defective -amyloid clearance pathways in aging alzheimer's disease mice Journal of Neuroscience 2008 28 33 8354 8360
24. Streit W. J., Miller K. R., Lopes K. O., Njie E., Microglial degeneration in the aging brainbad news for neurons? Frontiers in Bioscience 2008 13 9 3423 3438 (Pubitemid 351594693)
25. Lucin K. M., Wyss-Coray T., Immune activation in brain aging and neurodegeneration: too much or too little? Neuron 2009 64 1 110 122
26. Frautschy S. A., Yang F., Irrizarry M., Hyman B., Saido T. C., Hsiao K., Cole G. M., Microglial response to amyloid plaques in APPsw transgenic mice American Journal of Pathology 1998 152 1 307 317 (Pubitemid 28028071)
27. Cimino P. J., Keene C. D., Breyer R. M., Montine K. S., Montine T. J., Therapeutic targets in prostaglandin E2 signaling for neurologic disease Current Medicinal Chemistry 2008 15 19 1863 1869
28. Kaushal V., Koeberle P. D., Wang Y., Schlichter L. C., The Ca 2+ -activated K + channel KCNN4/KCa3.1 contributes to microglia activation and nitric oxide-dependent neurodegeneration Journal of Neuroscience 2007 27 1 234 244 (Pubitemid 46089977)
29. Chen Y. J., Raman G., Bodendiek S., O'Donnell M. E., Wulff H., The KCa3.1 blocker TRAM-34 reduces infarction and neurological deficit in a rat model of ischemia/reperfusion stroke Journal of Cerebral Blood Flow and Metabolism 2011 31 12 2363 2374
30. Bouhy D., Ghasemlou N., Lively S., Redensek A., Rathore K.I., Schlichter L.C., David S., Inhibition of the Ca 2+ -dependent K + channel, KCNN4/KCa3.1, improves tissue protection and locomotor recovery after spinal cord injury The Journal of Neuroscience 2011 31 16298 16308
31. Harmar A. J., Hills R. A., Rosser E. M., Jones M., Buneman O. P., Dunbar D. R., Greenhill S. D., Hale V. A., Sharman J. L., Bonner T. I., Catterall W. A., Davenport A. P., Delagrange P., Dollery C. L., Foord S. M., Gutman G. A., Laudet V., Neubig R. R., Ohlstein E. H., Olsen R. W., Peters J., Pin J. P., Ruffolo R. R., Searls D. B., Wright M. W., Spedding M., IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels Nucleic Acids Research 2009 37 1 D680 D685
32. Wulff H., Castle N. A., Pardo L. A., Voltage-gated potassium channels as therapeutic targets Nature Reviews Drug Discovery 2009 8 12 982 1001
33. Cahalan M. D., Chandy K. G., The functional network of ion channels in T lymphocytes Immunological Reviews 2009 231 1 59 87
34. Ghanshani S., Wulff H., Miller M. J., Rohm H., Neben A., Gutman G. A., Cahalan M. D., Chandy K. G., Up-regulation of the IKCa1 potassium channel during T-cell activation: molecular mechanism and functional consequences The Journal of Biological Chemistry 2000 275 47 37137 37149 (Pubitemid 32002132)
35. Wulff H., Calabresi P. A., Allie R., Yun S., Pennington M., Beeton C., Chandy K. G., The voltage-gated Kv1.3 K + channel in effector memory T cells as new target for MS Journal of Clinical Investigation 2003 111 11 1703 1713 (Pubitemid 38057751)
36. Wulff H., Knaus H. G., Pennington M., Chandy K. G., K + channel expression during B cell differentiation: implications for immunomodulation and autoimmunity Journal of Immunology 2004 173 2 776 786 (Pubitemid 38924252)
37. Di L., Srivastava S., Zhdanova O., Ding Y., Li Z., Wulff H., Lafaille M., Skolnik E. Y., Inhibition of the K + channel KCa3.1 ameliorates T cell-mediated colitis Proceedings of the National Academy of Sciences of the United States of America 2010 107 4 1541 1546
38. Schilling T., Stock C., Schwab A., Eder C., Functional importance of Ca 2+ -activated K + channels for lysophosphatidic acid-induced microglial migration European Journal of Neuroscience 2004 19 6 1469 1474 (Pubitemid 38437909)
39. Khanna R., Roy L., Zhu X., Schlichter L. C., K + channels and the microglial respiratory burst American Journal of Physiology 2001 280 4 C796 C806
40. Wulff H., Castle N. A., Therapeutic potential of KCa3.1 blockers: recent advances and promising trends Expert Review of Clinical Pharmacology 2010 3 3 385 396
41. Joiner W. J., Wang L. U. Y., Tang M. D., Kaczmarek L. K., hSK4, a member of a novel subfamily of calcium-activated potassium channels Proceedings of the National Academy of Sciences of the United States of America 1997 94 20 11013 11018 (Pubitemid 27430852)
42. Ishii T. M., Silvia C., Hirschberg B., Bond C. T., Adelman J. P., Maylie J., A human intermediate conductance calcium-activated potassium channel Proceedings of the National Academy of Sciences of the United States of America 1997 94 21 11651 11656 (Pubitemid 127650718)
43. Logsdon N. J., Kang J., Togo J. A., Christian E. P., Aiyar J., A novel gene, hKCa4, encodes the calcium-activated potassium channel in human T lymphocytes The Journal of Biological Chemistry 1997 272 52 32723 32726 (Pubitemid 28023600)
44. Wulff H., Miller M. J., Hnsel W., Grissmer S., Cahalan M. D., Chandy K. G., Design of a potent and selective inhibitor of the intermediate- conductance Ca 2+ -activated K + channel, IKCa1: a potential immunosuppressant Proceedings of the National Academy of Sciences of the United States of America 2000 97 14 8151 8156 (Pubitemid 30460788)
45. Wulff H., Kolski-Andreaco A., Sankaranarayanan A., Sabatier J. M., Shakkottai V., Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications Current Medicinal Chemistry 2007 14 13 1437 1457 (Pubitemid 46902225)
46. Khler R., Wulff H., Eichler I., Kneifel M., Neumann D., Knorr A., Grgic I., Kmpfe D., Si H., Wibawa J., Real R., Borner K., Brakemeier S., Orzechowski H. D., Reusch H. P., Paul M., Chandy K. G., Hoyer J., Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis Circulation 2003 108 9 1119 1125 (Pubitemid 37071524)
47. Toyama K., Wulff H., Chandy K. G., Azam P., Raman G., Saito T., Fujiwara Y., Mattson D. L., Das S., Melvin J. E., Pratt P. F., Hatoum O. A., Gutterman D. D., Harder D. R., Miura H., The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans Journal of Clinical Investigation 2008 118 9 3025 3037
48. Tharp D. L., Wamhoff B. R., Wulff H., Raman G., Cheong A., Bowles D. K., Local delivery of the KCa3.1 blocker, TRAM-34, prevents acute angioplasty-induced coronary smooth muscle phenotypic modulation and limits stenosis Arteriosclerosis, Thrombosis, and Vascular Biology 2008 28 6 1084 1089
49. Newell E. W., Stanley E. F., Schlichter L. C., Reversed Na+/Ca 2+ exchange contributes to Ca 2+ influx and respiratory burst in microglia. Channels (Austin, Tex.) 2007 1 5 366 376
50. Reich E. P., Cui L., Yang L., Pugliese-Sivo C., Golovko A., Petro M., Vassileva G., Chu I., Nomeir A. A., Zhang L. K., Liang X., Kozlowski J. A., Narula S. K., Zavodny P. J., Chou C. C., Blocking ion channel KCNN4 alleviates the symptoms of experimental autoimmune encephalomyelitis in mice European Journal of Immunology 2005 35 4 1027 1036 (Pubitemid 40542209)
51. Caughey B., Lansbury P. T., Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders Annual Review of Neuroscience 2003 26 267 298 (Pubitemid 37064935)
52. Necula M., Kayed R., Milton S., Glabe C. G., Small molecule inhibitors of aggregation indicate that amyloid oligomerization and fibrillization pathways are independent and distinct The Journal of Biological Chemistry 2007 282 14 10311 10324 (Pubitemid 47093410)
53. Glabe C. G., Structural classification of toxic amyloid oligomers The Journal of Biological Chemistry 2008 283 44 29639 29643
54. Lambert M. P., Barlow A. K., Chromy B. A., Edwards C., Freed R., Liosatos M., Morgan T. E., Rozovsky I., Trommer B., Viola K. L., Wals P., Zhang C., Finch C. E., Krafft G. A., Klein W. L., Diffusible, nonfibrillar ligands derived from A 1-42 are potent central nervous system neurotoxins Proceedings of the National Academy of Sciences of the United States of America 1998 95 11 6448 6453
55. Lesné S., Ming T. K., Kotilinek L., Kayed R., Glabe C. G., Yang A., Gallagher M., Ashe K. H., A specific amyloid- protein assembly in the brain impairs memory Nature 2006 440 7082 352 357
56. Shankar G. M., Li S., Mehta T. H., Garcia-Munoz A., Shepardson N. E., Smith I., Brett F. M., Farrell M. A., Rowan M. J., Lemere C. A., Regan C. M., Walsh D. M., Sabatini B. L., Selkoe D. J., Amyloid- protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory Nature Medicine 2008 14 8 837 842
57. Roychaudhuri R., Yang M., Hoshi M. M., Teplow D. B., Amyloid -protein assembly and Alzheimer disease The Journal of Biological Chemistry 2009 284 8 4749 4753
58. Wang Q., Rowan M. J., Anwyl R., -amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide Journal of Neuroscience 2004 24 27 6049 6056 (Pubitemid 38891095)
59. Begenisich T., Nakamoto T., Ovitt C. E., Nehrke K., Brugnara C., Alper S. L., Melvin J. E., Physiological roles of the intermediate conductance, Ca 2+ - activated potassium channel Kcnn4 The Journal of Biological Chemistry 2004 279 46 47681 47687 (Pubitemid 39540914)
60. Si H., Heyken W. T., Wlfle S. E., Tysiac M., Schubert R., Grgic I., Vilianovich L., Giebing G., Maier T., Gross V., Bader M., De Wit C., Hoyer J., Khler R., Impaired endothelium-derived hyperpolarizing factor-mediated dilations and increased blood pressure in mice deficient of the intermediate-conductance Ca 2+ -activated K + channel Circulation Research 2006 99 5 537 544 (Pubitemid 44337826)
61. Grgic I., Kaistha B. P., Paschen S., Kaistha A., Busch C., Si H., Khler K., Elssser H. P., Hoyer J., Khler R., Disruption of the Gardos channel (KCa3.1) in mice causes subtle erythrocyte macrocytosis and progressive splenomegaly Pflugers Archiv European Journal of Physiology 2009 458 2 291 302
62. Ataga K. I., Orringer E. P., Styles L., Vichinsky E. P., Swerdlow P., Davis G. A., DeSimone P. A., Stocker J. W., Dose-escalation study of ICA-17043 in patients with sickle cell disease Pharmacotherapy 2006 26 11 1557 1564 (Pubitemid 44704467)
63. Ataga K. I., Smith W. R., De Castro L. M., Swerdlow P., Saunthararajah Y., Castro O., Vichinsky E., Kutlar A., Orringer E. P., Rigdon G. C., Stacker J. W., Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia Blood 2008 111 8 3991 3997